http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S60139619-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c6e8c5865a497d2301eb7fac35a0b3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9575aa9deffac891c58962bae1ee889 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-04 |
| filingDate | 1983-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8dd74c3d3854bb70cae68b566270320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27840abeb169b18adb29bcc03715b38b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afa676652082826ae9e4c9c88170d4d3 |
| publicationDate | 1985-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S60139619-A |
| titleOfInvention | Antitumor agent comprising o-bnezylidene-ascorbic acid or its salt |
| abstract | PURPOSE: An antitumor agent showing high water-solubility, comprising 5,6-O- benzylidene-L-ascorbic acid or its salt as an active ingredient. n CONSTITUTION: An antitumor agent containing 0.1W20wt% 5,6-O-benzylidene-L- ascorbic acid shown by the formula or its salt as an active ingredient in the case of oral or mucosa absorption, and 0.01W10wt% 5,6-benzyl-O-ascorbic acid or its salt in the case of parenteral absorption. The compound shown by the formula as an active ingredient is obtained by reacting L-ascorbic acid with α,α- dimethoxytoluene in dimethyl sulfoxide, etc. in the presence of an acid catalyst (e.g., p-toluenesulfonic acid, etc.) under heating. The antitumor agent can be administered orally or parenterally, and as dosage form, capsule, tablet, fine granule, powder, injection, ophthalmic solution, suppository, etc. may be cited. A dose is 500W1,000g/day/person. n COPYRIGHT: (C)1985,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9535106-A1 |
| priorityDate | 1983-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.